MannKind of Santa Clarita reported Thursday that expenses across the board declined significantly in the first quarter of 2015, compared to the same period in 2014, as a result of the FDA’s approval of Afrezza last year.
First quarter operating expenses declined nearly 48 percent to $21.7 million. Research and development expenses declined 64.2 percent to $9.4 million.
General and administrative expenses declined 31.2 percent to $10.5 million in the first quarter, compared to the prior year.
Net losses for the quarter were $30.7 million – an improvement, however, over net losses of $52.1 million the prior year.
MannKind’s portion of the loss sharing arrangement with Sanofi was $12.4 million. The biomedical company entered into a partnership with Paris-based Sanofi last year, to market and distribute the diabetes treatment inhaler Afrezza.
For the period ending March 31, MannKind recorded $7.1 million in Afrezza shipments.
